Close Menu
NEW YORK (GenomeWeb News) - Investment firm Caris & Company upgraded Illumina's stock to "Buy" from "Above Average" today.
 
The broker cited "removal of Markman ruling overhang" as the reason behind the upgrade.
 
Separately today, investment bank UBS lifted Affymetrix' price target to $20 from $18.
 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.